Loading stock data…
OMCL
$40.69-1.26 (-3.00%)
After Hours$40.69+0.00 (+0.00%)· Last close Jun 9
Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Omnicell, Inc. in the Healthcare sector is trading at $40.69 with a market capitalization of $1.9B. Wall Street consensus targets $61.29 (7 analysts), implying a +50.6% move over the next 12 months. The stock is currently 26% below its 52-week high of $55.00, remaining 5.6% above its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +50.6% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$40.69
Potential Downside
6.1%
Whystock Fair Value$38.21
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the heal...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.91B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
95.20
Beta
Defensive asset. Lower volatility than the S&P 500.
0.96
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
1.63%
Volume
Today's trading volume
667,036
Recent News
1 Profitable Stock with Exciting Potential and 2 That Underwhelm
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.
3 Russell 2000 Stocks That Fall Short
The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However, these companies often come with higher volatility and risk, as their smaller size makes them more vulnerable to economic downturns.
Omnicell Shareholders Back Governance Amendment And Long Term Growth Focus
Shareholders of Omnicell (NasdaqGS:OMCL) have approved an amendment to the company's Amended and Restated Certificate of Incorporation. The vote took place at Omnicell's recent annual meeting, signaling investor support for changes to the company's foundational governing document. For investors following Omnicell, this governance change comes with the stock at a share price of $43.0. The company has seen its share price rise 38.7% over the past year, while longer term returns have been...
Wall Street Analysts Predict a 40.57% Upside in Omnicell (OMCL): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 40.6% in Omnicell (OMCL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Omnicell (OMCL) is a Top-Ranked Momentum Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.